2 studies found for:    8760792 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Terminated
Has Results
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
Conditions: Metastatic Melanoma;   Metastatic Renal Cancer
Interventions: Drug: Zanolimumab;   Drug: Aldesleukin
2 Completed Biological Markers in Retinal Vasculitis
Condition: Retinal Vasculitis
Intervention:

Indicates status has not been verified in more than two years